Dermata (DRMA) receives Australian patent for topical botulinum toxin treatment

Dermata Therapeutics, Inc. (NASDAQ: DRMA) announced Tuesday that the Australian Patent Office has granted its patent application for its DMT410 program for the treatment of hyperhidrosis. The patent, entitled "Compositions for the treatment of skin conditions," represents the company's second granted patent for DMT410.

DMT410 is a combination treatment that uses Dermata's XYNGARI product candidate to facilitate topical delivery of botulinum toxin rather than through needle injections. The treatment involves applying XYNGARI to create microchannels in the skin, allowing for topical application and penetration of botulinum toxin.

The company has completed proof-of-concept Phase 1 clinical trials using DMT410 in combination with BOTOX for primary axillary hyperhidrosis treatment and for aesthetic skin conditions. Both studies showed efficacy results and appeared safe and well tolerated by patients, according to the press release.

Dermata recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for axillary hyperhidrosis treatment. The company is also planning to initiate a Phase 2a study of DMT410 using XYNGARI with DAXXIFY for axillary hyperhidrosis treatment.

"We believe this patent reinforces our commitment to pushing boundaries for standard of care for hyperhidrosis patients," said Gerry Proehl, Dermata's Chairman, President, and CEO. He noted potential applications for palmer and plantar hyperhidrosis, which he described as high unmet needs for patients.

Dermata is a late-stage biotechnology company focusing on medical skin diseases and aesthetic applications. The company's lead product candidate, XYNGARI, recently achieved positive data in a Phase 3 STAR-1 study for moderate-to-severe acne treatment.

You May Also Be Interested In

• Kala Bio signs exclusive U.S. deal to distribute Virotek eye genetic tests
• Olenox converts $5.25M in debt and preferred stock to equity
• Alcon launches Unity M ophthalmic microscope in U.S. and Japan